February 10, 2020 / 6:15 AM / 11 days ago

Roche drug fails in early-onset Alzheimer's disease study

ZURICH, Feb 10 (Reuters) - Roche said its experimental Alzheimer's disease drug gantenerumab did not show a significant slowing of the rate of cognitive decline in people with a rare inherited form of the devastating brain wasting disease.

Roche said the study's failure will not impact two ongoing late-stage studies of gantenerumab in people with common form of Alzheimer's disease that is not directly caused by gene mutations. (Reporting by John Miller; editing by Thomas Seythal)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below